Forecast

The analysts' average price target is +36,18€ (+44,60%). The median is +36,89€ (+47,44%).

Buy	19
Hold	2
Sell	0

News Go to news feed

Zymeworks receives FDA approval for Ziihera, analyst raises price target to $55

The U.S. approval of the cancer drug Ziihera triggers a contractual one-time payment of $0.25 billion to Zymeworks. H.C. Wainwright raised the price target from $51 to $55 and reaffirmed the buy recommendation. Zymeworks' business model combines in-house research with strategic partners and benefits from oncology growth trends. » More on finanzen.net
Zymeworks rises ahead of FDA decision on zanidatamab

Zymeworks shares climbed in premarket trading as the FDA decision on the PDUFA date of August 25, 2026, for zanidatamab (Ziihera) for HER2-positive gastric and gastroesophageal adenocarcinoma is awaited. Approval would immediately trigger a U.S. milestone payment of $250 million and could enable further global payments of up to $190 million. Analysts backed their assessments and raised price targets ahead of the date, and the planned acquisition of Theravance Biopharma is expected to strengthen the portfolio and cash flows with YUPELRI. The share price rise comes despite a weak overall market and a difficult biotech environment; the stock is trading at its highest level in more than a year. » More on de.investing.com
Zymeworks rises after partnership with Gandeeva for cryo‑EM structural analyses

Zymeworks has entered a collaboration with Gandeeva Therapeutics to generate cryo‑electron microscopy structural data to aid discovery of antibody therapeutics. The partnership focuses on high‑resolution visualization of antibody‑antigen interfaces, in particular epitope mapping on small, flexible antigens. Gandeeva has already demonstrated a structure determination at 2.6 Å resolution that is intended to support selection and optimization of antibody lead candidates. In response, Zymeworks shares rose sharply in pre‑market trading. » More on de.investing.com

Financials

In the last quarter, Zymeworks had revenue of 4.02m€ and net profit of −39.45m€

(EUR)	Jun 2026	YoY
Revenue	+4.02m	90,27%
Gross profit	+4.02m	90,27%
Net profit	−39.45m	2.106,63%
EBITDA	−37.69m	1.814,75%

Fundamentals

Metric	Value
Market capitalization	+1.83b€
Number of shares	73.57m
52-week high/low	+26,27€ - +11,67€
Dividends	No
Beta	1,15
P/E ratio	−14,35
PEG ratio	+0,21
P/B ratio	+26,33
P/S ratio	+57,45

Company profile

Zymeworks Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das Biotherapeutika für die Behandlung von Krebs entdeckt, entwickelt und vermarktet. Zu den führenden Produktkandidaten des Unternehmens gehören Zanidatamab, ein neuartiger bispezifischer Antikörper, der sich in klinischen Studien der Phasen 1 und 2 zur Behandlung von Gallenwegs-, gastroösophagealen Adenokarzinomen, Brust- und Darmkrebs befindet, sowie ZW49, ein biparatopisches Antikörper-Wirkstoff-Konjugat gegen den humanen epidermalen Wachstumsfaktor-Rezeptor 2 (HER2), das sich in einer klinischen Studie der Phase 1 zur Behandlung fortgeschrittener oder metastasierender HER2-exprimierender Tumore befindet. Das Unternehmen unterhält strategische Partnerschaften mit Merck Sharp & Dohme Research Ltd, Eli Lilly and Company, Bristol-Myers Squibb Company, GlaxoSmithKline Intellectual Property Development Ltd, Daiichi Sankyo Co, Ltd, Janssen Biotech, Inc, BeiGene, Ltd und Exelixis, Inc. Darüber hinaus bestehen Lizenz- und Forschungskooperationen mit LEO Pharma A/S zur Erforschung, Entwicklung und Vermarktung von bispezifischen Antikörpern sowie mit Iconic Therapeutics, Inc. Zymeworks Inc. wurde im Jahr 2003 gegründet und hat seinen Hauptsitz in Vancouver, Kanada.

Name	Zymeworks
CEO	Kenneth H. Galbraith
Headquarters	Middletown, de Canada
Website	zymeworks.com
Sector	Health Care
Industry	Biotechnology
IPO	04/28/2017
Employees	231